

Developmental Cell

CXCL12 Signaling Is Essential for Maturation of the Ventricular Coronary Endothelial Plexus and Establishment of Functional Coronary Circulation

Highlights

- CXCL12 is a vascular maturation factor important in coronary artery development
- CXCL12 acts in an organ-specific and paracrine manner
- Defective coronary formation explains late-gestation lethality of CXCL12 mutants
- The sinus venosus is the primary origin of embryonic coronary endothelium

Authors

Susana Cavallero, Hua Shen, ...,
S. Ram Kumar, Henry M. Sucov

Correspondence

ccavalle@usc.edu (S.C.),
sucov@usc.edu (H.M.S.)

In Brief

Cavallero et al. show that CXCL12 is an organ-specific vascular maturation factor that promotes higher-order complexity of preinitiated vessels. In the heart, deficiency in CXCL12/CXCR4 signaling results in a poorly formed coronary system and insufficient myocardial perfusion, and accounts for late-gestation lethality seen in these mutants.



CXCL12 Signaling Is Essential for Maturation of the Ventricular Coronary Endothelial Plexus and Establishment of Functional Coronary Circulation

Susana Cavallero,^{1,*} Hua Shen,¹ Christopher Yi,² Ching-Ling Lien,^{2,3} S. Ram Kumar,² and Henry M. Sucov^{1,*}

¹Broad Center for Regenerative Medicine and Stem Cell Research

²Department of Surgery, Keck School of Medicine

University of Southern California, Los Angeles, CA 90033, USA

³Saban Research Institute of Children's Hospital, Los Angeles, CA 90027, USA

*Correspondence: ccavalle@usc.edu (S.C.), sucov@usc.edu (H.M.S.)

<http://dx.doi.org/10.1016/j.devcel.2015.03.018>

SUMMARY

Maturation of a vascular plexus is a critical and yet incompletely understood process in organ development, and known maturation factors act universally in all vascular beds. In this study, we show that CXCL12 is an organ-specific maturation factor of particular relevance in coronary arterial vasculature. *In vitro*, CXCL12 does not influence nascent vessel formation, but promotes higher-order complexity of preinitiated vessels. In the heart, CXCL12 is expressed principally by the epicardium, and its receptor CXCR4 is expressed by coronary endothelial cells. CXCL12 is not a chemotactic signal for endothelial cell migration, but rather acts in a paracrine manner to influence the maturation of the coronary vascular plexus. Mutants in CXCL12 signaling show an excess of immature capillary chains and a selective failure in arterial maturation, and become leaky with the onset of coronary perfusion. Failed maturation of the coronary system explains the late-gestation lethality of these mutants.

INTRODUCTION

Formation of the vascular system is tightly regulated by the spatial and temporal expression of various factors (Jain, 2003). Vascular endothelial growth factor (VEGF) promotes the assembly of endothelial progenitors into a nascent immature plexus (Ferrara et al., 1996; Carmeliet et al., 1996) and also promotes specification to an arterial fate (Hong et al., 2006; Lawson et al., 2002; Mukoyama et al., 2005). The newly formed plexus then undergoes a complex and incompletely understood process of vascular maturation that involves pruning and reorganization into a hierarchical network of larger and smaller arteries and veins; for arteries, plexus maturation also involves assembly of a surrounding layer of smooth muscle. Connection to systemic circulation initiates perfusion and additional remodeling processes that continue through life. Several signaling pathways have been implicated in plexus maturation, including angiopoietin (Suri et al., 1998), ephrin

(Wang et al., 1998), and Notch (Duarte et al., 2004), although these appear to be universally required in all vascular compartments. In contrast, there is also evidence for organ-specific maturation processes that are thought to be controlled by unique locally expressed molecules (Jain, 2003; Wang et al., 2012), although few if any such factors have been identified.

In mouse heart development, cells from the proepicardium migrate onto and adhere to the outer myocardial surface between embryonic days E9.5 and E10.5, forming the epicardium (Sengbusch et al., 2002). Coronary endothelial cells first assemble into a plexus in the space between the epicardium and ventricular myocardium, then associate with epicardium-derived smooth muscle cells as the nascent tubes coalesce and become incorporated into the ventricular wall (Red-Horse et al., 2010). Coronary veins remain close to the outer surface, whereas coronary arteries become more deeply positioned. Ingrowth of the anterior ends of the arteries into the ascending aorta at E14 initiates perfusion and coronary circulation (Chen et al., 2014; Tian et al., 2013a). The molecular signals that promote differentiation of the primitive plexus to assemble the mature coronary vasculature of the embryonic ventricular wall are largely unknown.

The chemokine CXCL12, also known as SDF1, has chemotactic and mitogenic activity on many cell types (Nagasawa, 2014). Various nonexclusive roles for CXCL12 signaling in vasculogenesis have been proposed, including endothelial cell migration (Siekmann et al., 2009), arterial-nerve alignment (Li et al., 2013), and mediation of plexus connections to systemic arteries (Ara et al., 2005). CXCL12 primarily acts through the G protein coupled receptor CXCR4; global mouse knockouts of *Cxcl12* or of *Cxcr4* die shortly before birth with vascular deficiencies in the gut, kidney, and skin, and with a number of additional hematopoietic and neural defects (Ma et al., 1998; Nagasawa et al., 1996; Tachibana et al., 1998; Zou et al., 1998). Endothelium-specific *Tie2Cre/Cxcr4* mutants replicate the vascular phenotype of global mutants (Ara et al., 2005; Takabatake et al., 2009). Except for an unexplained ventricular septal defect, cardiac development was not closely examined. Importantly, the known defects cannot explain the late-gestation lethality seen in the global or conditional mutants.

In the present study, we found that CXCL12 has potent activity in vascular plexus maturation, although not in the initial assembly of the vascular plexus. We demonstrate that this function is particularly relevant in the maturation of the coronary arterial




Figure 1. CXCL12 Promotes Plexus Maturation In Vitro

(A–L) Representative images of HUVEC-covered beads in fibrin gels after 3, 5, and 7 days of culture. Note the absence of sprouting in control conditions (A, E, I) or with CXCL12 alone (B, F, J). VEGF induced sprouting at 3 days (C) and the formation of tubes at 5 and 7 days (G, K). Treatment with VEGF plus CXCL12 (D, H, L) increased the complexity of the endothelial network by days 5 and 7. The negative control was endothelial basal media (EBM-2) plus 2% FBS with no added growth factors; VEGF and CXCL12 were added at 20 ng/ml and 100 ng/ml, respectively. (M) Quantitation of total number of sprouts, tubes, branching points, and anastomosis in the fibrin bead assay. The data are normalized to the number of beads present in each microscopic field. Data are represented as mean ± SEM. *p < 0.001 versus VEGF alone. See also Figure S1.

branches with other tubes (Figures S1A–S1E). Using this assay, we measured initial endothelial cell sprouting at 3 days and the complexity of lumenized tubes at 5 days to test the role of CXCL12 and its possible interaction with VEGF. In the absence of added factors (Figures 1A, 1E, and 1I) or with CXCL12 alone (Figures 1B, 1F, and 1J), no outgrowth occurred even as late as 7 days after plating. VEGF induced sprouting at 3 days (Figure 1C) and formation of tubes at 5 days (Figure 1G), as previously reported (Nakatsu et al., 2003). Addition of the CXCR4 antagonist AMD3100 to VEGF-treated cultures had no effect (Figure S1F), indicating that CXCL12 is not made by endogenous components of this assay and that CXCR4 is not required for the VEGF response. The number of primary sprouts that originated from each bead was unchanged when CXCL12 was added with VEGF (Figures 1D and 1M). CXCL12 also did not influence VEGF-induced changes in HUVEC arterial or

venous gene expression (Figure S1I). However, the combination of CXCL12 with VEGF dramatically increased the complexity of the endothelial tube network by day 5, as manifest both by the number of tubes (i.e., primary tubes plus branched tubes) and by the number of anastomoses between tubes (Figures 1H and 1M). Thus, in vitro, CXCL12 does not initiate vasculogenesis or alter arterial-venous specification but rather promotes further remodeling of a plexus that is initially induced by VEGF (Figure S1H).

RESULTS

CXCL12 Promotes Higher-Order Vascular Plexus Organization In Vitro

Many aspects of early vascular plexus formation and maturation are modeled by the behavior of HUVEC endothelial cells in fibrin gels (Nakatsu et al., 2003), including the formation of vascular sprouts, lumenized tubes, branches, and anastomoses of

venous gene expression (Figure S1I). However, the combination of CXCL12 with VEGF dramatically increased the complexity of the endothelial tube network by day 5, as manifest both by the number of tubes (i.e., primary tubes plus branched tubes) and by the number of anastomoses between tubes (Figures 1H and 1M). Thus, in vitro, CXCL12 does not initiate vasculogenesis or alter arterial-venous specification but rather promotes further remodeling of a plexus that is initially induced by VEGF (Figure S1H).

CXCL12 Expression during the Period of Mouse Coronary Vessel Formation

The majority of coronary endothelial cells of the embryonic ventricular wall are thought to originate from the sinus venosus




Figure 2. CXCL12 and CXCR4 Expression during Coronary Vessel Development

(A–F) In situ hybridization with antisense probe for *Cxcl12* shows expression in the epicardium in wild-type embryos. (A) *Cxcl12* is expressed in the epicardium surrounding the atrioventricular canal at E10.5. (B) Hybridization with a sense control. (A') and (B') are magnified views of the boxed region in (A) and (B). (C–F) *Cxcl12* is expressed in the epicardium at E11.5 (C), E12.5 (D), E14.5 (E), and in both epicardium and epicardium-derived smooth muscle surrounding coronary blood vessels (arrowheads) at E16.5 (F).

(G–I) CXCR4 is expressed in endothelial cells sprouting from the sinus venosus at E11.5 (arrowheads). The dotted lines outline the pericardial cavity. CD31 (Pecam1), a pan-endothelial marker (green, G), CXCR4 (red, H), and merged channels (I) are shown.

Abbreviations: oft, outflow tract; ra, right atria; rv, right ventricle; avc, atrioventricular canal; sv, sinus venosus; li, liver; epi, epicardium. See also Figure S2.

and migrate between the epicardium and myocardium (Red-Horse et al., 2010; see also below). In mice, this process initiates at embryonic day E11.5 on the dorsal side of the heart at the atrioventricular canal, with expansion and maturation of the plexus occurring over the next several days. *Cxcl12* was expressed throughout the E10.5–E16.5 interval in the epicardium (Figures 2A–2F); this included the epicardium of the atrioventricular canal and over the ventricle. *Cxcl12* may also be expressed at a uniform low level in the myocardium; we measured 4-fold lower expression in isolated primary embryonic ventricular cardiomyocytes compared with primary ventricular epicardial cells (Figure S2A). *Cxcl12* expression was also detected in the wall of the aorta during this period (Figure S2B), by cells of presumptive neural crest origin (Choudhary et al., 2009). Consistent with epicardial expression in vivo,

CXCL12 is secreted at an abundant level by immortalized MEC1 mouse embryonic ventricular epicardial cells (Figure S2C). In MEC1 and in primary mouse embryonic epicardial cells, the *Cxcl12* gene was induced by hypoxia (Figure S2D), as observed in other cell types (Santiago et al., 2011; Sun et al., 2010). *Cxcl12* was expressed later by epicardium-derived smooth muscle cells surrounding mature coronary blood vessels (Figure 2F). The receptor *Cxcr4* was expressed at E11.5 in sinus venosus endothelium, in endothelial cells sprouting from the sinus venosus toward the ventricle, and in heart endocardium (Figures 2G–2I; Figures S2E–S2G), a pattern identical to the venous marker endomucin (Emcn) (Figures S2H–S2N). Thus, the spatial and temporal expression of *Cxcl12* and *Cxcr4* are consistent with a role in coronary vascular development.




Figure 3. Defective Coronary Vessel Organization in Embryos with Disrupted CXCL12 Signaling

(A–H) Whole-mount CD31 immunostaining of hearts (dorsal surfaces) from control (A–D) and conditional *Tie2Cre/Cxcr4* mutants (E–H) at the indicated stages. Dotted lines indicate the extent of endothelial cell plexus organization within the ventricle. The diffuse staining at E11.5 on the ventricular surface corresponds to CD31-positive endocardium (open arrowheads). Views of the ventral surfaces of these same hearts are in Figure S3.

(I–L) Histological sections of control (I and J) and mutant (K and L) hearts at E13.5 immunostained with CD31 and endomucin (EMCN, venous marker). In the control (J), superficial veins are EMCN-positive (arrows). In the mutant (L), the open arrowhead in center points to an intramyocardial vessel ectopically expressing endomucin, and the open arrowhead to the right points to a superficial dilated EMCN-negative vessel.

(M and N) Reduced number of major coronary artery branches (SM22⁺) in mutants (N) compared with controls (M) at E15.5.

(legend continued on next page)

CXCL12/CXCR4 Signaling Is Required for Coronary Vascular Maturation

We evaluated global *Cxcl12*^{-/-} embryos and *Tie2Cre/Cxcr4* conditional mutant embryos to determine the role of CXCL12/CXCR4 in coronary vasculogenesis. At E12.0, the number of ventricular subepicardial endothelial cells, as visualized by CD31 immunostaining (a pan-endothelial marker), was normal in mutant embryos (Figures S3A and S3B), implying that CXCL12 signaling is not required for chemotactic migration of endothelial cells to the ventricle. Using whole-mount CD31 immunohistochemistry to visualize the forming vascular plexus, we noted an expansion in mutant hearts compared with littermate controls, on the dorsal ventricular surface at E11.5 and on the ventral (anterior) surface at E12.5 (Figures 3A and 3E; Figures S3C, S3D, S3G, and S3K, quantitated in Figure S3E). The expanded plexus in mutants included the peritruncal endothelium (Figure S3K) from which the proximal coronary stems are thought to originate (Tian et al., 2013a). Thus, just as addition of CXCL12 does not promote initial vascular assembly in vitro (Figure 1), absence of CXCL12 signaling does not impede initial coronary plexus assembly in vivo. The expanded plexus in mutant embryos is characteristic of a deficiency in maturation, since plexus maturation includes pruning (elimination) of a subset of capillary sprouts pursuant to remodeling into higher order vessels. As the coronary plexus matures, arteries migrate deeper into the myocardium, whereas veins remain close to the ventricular surface. Using endomucin (Emcn) as a venous marker, in mutant hearts we observed many examples of CD31⁺Emcn⁻ vessels at the subepicardial ventricular surface, and CD31⁺Emcn⁺ vessels in deeper intramyocardial arterial positions, whereas such mispositioned vessels were never seen in control embryos (Figures 3J and 3L). Mispositioning is consistent with persistence of vessels that should have been eliminated from the earlier expanding plexus. Moreover, intramyocardial vessels in mutants showed only weak expression of the arterial marker NRP1 (Figures S3N–S3Q), and there were fewer intramyocardial arteries that displayed an SM22⁺ smooth muscle lining in mutants relative to controls (Figures 3M and 3N), both implying compromised arterial differentiation. Thus, maturation of the coronary plexus is compromised in the absence of CXCL12-CXCR4 signaling, which is manifest by a transiently expanded but ultimately unreorganized and poorly differentiated vascular network.

Embryos with Deficient CXCL12 Signaling Have Severely Compromised Coronary Arterial Vasculature

Whole-mount endomucin staining of mutant E15.5 hearts indicated normal higher order organization of the venous compo-

nent of the coronary vasculature (Figures 3O and 3P). Thus, CXCL12 signaling is not required for venous coronary maturation. We performed aortic ink perfusion to visualize the organization of the coronary arterial vasculature in control and mutant embryos in late gestation (Figures 3Q–3T; Figures S4A–S4C). In normal hearts, the main proximal coronary branches give rise to arteries of progressively smaller diameter that perfuse the entire ventricle to the apex. In mutant hearts, in the vicinity of the aorta we generally observed only a poorly differentiated plexus that quickly terminated. When main proximal branches were present, these also quickly terminated. The deficiency of the peripheral arterial network in late-gestation mutant embryos was not the result of absent vascular elements, because in sections an abundance of small vessels was apparent in the ventricular wall (Figures 3U and 3V). Many of these intramyocardial vessels lacked a SM22⁺ smooth muscle lining and were therefore either mispositioned veins or immature vessels persisting from the vascular plexus of earlier stages, although some SM22⁺ arteries were also detected, consistent with the presence of some arteries as visualized by ink perfusion. Importantly, at least some proximal components of the coronary system were perfused with ink in all mutant embryos (Figures 3R and 3T; Figures S4B and S4C), implying connection to the aorta, and coronary ostia and proximal branches were readily observed in mutant embryos (Figures 3W and 3X; Figures S4C–S4F). CXCL12/CXCR4 signaling does not therefore appear to be required for coronary ostia formation.

Perfusion of the coronary arteries initiates around E14 (Tian et al., 2013a). The ventricular myocardium in mutants appeared normal through E15 (Figures S3R–S3U), but in late-gestation mutant embryos, we commonly observed ventricular hemorrhaging (Figures S4G and S4H), which we interpret as the result of an immature, leaky vascular network following the onset of coronary perfusion. As previously reported, *Cxcl12* global and *Tie2Cre/Cxcr4* mutants appeared macroscopically normal through E14.5; growth deficiency started at E15.5 and embryos varied in time of lethality between E16.5 and E18.5. The compromised coronary arterial network in mutant embryos is expected to result in impaired heart growth and function after the E14 onset of coronary perfusion, which would result in diminished embryo growth and ultimately in late-gestation embryo lethality.

Coronary Arterial Endothelial Cells Are Primarily Derived from an Extracardiac Origin

The ventricular endocardium is the source of coronary endothelium that forms after birth in the ventricular septum and inner ventricular wall (Tian et al., 2014). However, there is uncertainty regarding the cell lineage origin of embryonic coronary

(O and P) Whole-mount EMCN staining at E15.5, indicating normal assembly of higher order venous structures (arrowheads) in both mutant (P) and control (O). (Q–T) Visualization of the coronary arterial vasculature by aortic ink perfusion at E15.5 and E16.5. Arrowheads point to perfused vessels of abnormal branching organization in the mutant hearts (R and T) compared with controls (Q and S).

(U and V) Reduced number of major coronary artery branches in mutant hearts. (U) and (V) are low-magnification views of control and mutant hearts at E17.5 showing only SM22 (smooth muscle marker) staining. Close-up views of the boxed regions are shown in U', U'', V', and V'' with CD31 and SM22 immunostaining. Endothelial cell density is similar between control and mutant (compare U' with V'). Note smaller and fewer intramyocardial major branches (solid arrowheads) and dilated superficial vessels (open arrowheads) in the mutant.

(W and X) Close-up views of hearts from control (W, same as in Q) and *Cxcl12* KO (X, shown in Figure S4C). In the mutant, note perfusion of the proximal coronary artery from the aorta into the adjacent persisting capillary plexus.

Abbreviations: Ao, aorta; endo, endocardium; lca, left coronary artery; rca, right coronary artery; sb, septal branch; co, coronary ostia. See also Figure S3.




Figure 4. Coronary Endothelial Cells Are Derived from the Sinus Venosus

(A–C) *Nfatc1Cre* recombines in sinus venosus endothelial cell sprouts (three arrowheads at left) and in all endocardial cells at E11.5. (A) *Nfatc1Cre* recombination, (B) CD31 positive endothelial cells, and (C) merged channels are shown.

(D and E) *Nkx2.5Cre* recombination at E11.5. (E) corresponds to the boxed area in (D). *Nkx2.5Cre* does not recombine in endothelial cells (CD31⁺) of the sinus venosus and in endothelial cell sprouts of the sinus venosus moving toward the ventricle at the atrioventricular groove (open arrowheads).

(F) *Nkx2.5Cre* recombines efficiently in the myocardium, epicardium (arrows), and the majority of endocardial cells (solid arrowheads). A close-up confocal view of a trabecular element is shown in separate (F' and F'') and merged (F''') channels in the insets to emphasize that endocardial cells are labeled.

(G–I) *Nkx2.5Cre* recombination at E17.5. (G) shows a low-magnification view of the heart (green channel only). (H) and (I) correspond to the boxed areas in (G). *Nkx2.5Cre* does not recombine in coronary artery or vein endothelium throughout the mature ventricle.

(legend continued on next page)

endothelial cells, with the two principal sources argued to be either the sinus venosus (Red-Horse et al., 2010; Tian et al., 2013b) or the ventricular endocardium (Wu et al., 2012). *Tie2Cre* is active in both and so does not address this issue; *Nfatc1Cre*, which has been used in past studies to conclude an endocardial origin of coronary arterial endothelium (Wu et al., 2012), is also expressed in both (Figures 4A–4C). *Nkx2.5Cre* is active in the first and second heart fields and therefore efficiently labels the atrial and ventricular endocardium, myocardium, and epicardium, but is not active in most vascular endothelium, including that of the sinus venosus (Figures 4D–4F; Figures S4I–S4L). In normal hearts, the great majority (>90%) of coronary endothelial cells in the ventricular wall were unlabeled with the *Nkx2.5Cre* lineage marker, whereas the great majority (>90%) of endocardial cells and virtually all myocardial and epicardial cells were labeled. The absence of labeling was clearly evident in large and small caliber coronary arteries and in coronary veins (Figures 4G–4I; Figures S4K and S4L). The ~10% *Nkx2.5Cre* lineage-labeled coronary endothelial cells implies a degree of heterogeneity in the origin of this lineage, which was also noted in previous studies (Red-Horse et al., 2010). Furthermore, unlike the invariable late-gestation lethality of *Tie2Cre/Cxcr4* mutants, *Nkx2.5Cre/Cxcr4* mutants survived normally through adulthood with no apparent deficiencies. Ink injection in late-gestation *Nkx2.5Cre/Cxcr4* hearts demonstrated a normal coronary arterial pattern (Figures 4J and 4K), and the myocardium was also normal (Figures 4L and 4M). These results suggest that the endothelial cell lineage that responds to CXCL12 signaling through CXCR4 during maturation of the coronary vasculature originates from outside the *Nkx2.5Cre* domain of the heart. While we cannot exclude the possibility that a subset of endocardium that does not express *Nkx2.5* selectively contributes to coronary endothelium, our observations support an origin from the sinus venosus.

DISCUSSION

Maturation of the vascular plexus is critically required for adequate end-organ perfusion. Our studies show that CXCL12 is a necessary factor for coronary plexus maturation. *Cxcl12* and *Cxcr4* mutant embryos displayed a poorly formed coronary arterial network that resulted in late-gestation underperfusion of the heart, compromised heart growth and function, and embryo lethality, all manifestations of a failure in plexus maturation. For several reasons, we exclude a role for CXCL12 in earlier steps of coronary development. A previous study showed that signals from the ventricle are responsible for inducing migration of coronary endothelial cells from the sinus venosus (Red-Horse et al., 2010), but as we observed a normal density of endothelial cells at all stages in normal versus mutant embryos, this signal is not CXCL12. In *Cxcl12* or *Cxcr4* mutant embryos, initial plexus formation was normal (and was even expanded because of the lack of subsequent pruning), and in vitro, addition of CXCL12 did not influence VEGF-induced vascular sprouting. At the termi-

nal phase of coronary vasculogenesis, ingrowth of anterior arterial stems into the aorta results in the initiation of perfusion, and this too occurred normally in mutant embryos with arterial elements that had properly matured in the vicinity of the aorta. We thus conclude that CXCL12 acts in the ventricle as a vascular plexus maturation factor needed for arterial differentiation (with VEGF) and for hierarchical arterial assembly during coronary development.

Interestingly, hierarchical organization of the coronary venous system was normal in *Cxcl12* and *Cxcr4* mutants, implicating a specific role for this signaling axis in arterial maturation. The basis for this selectivity is unclear, but suggests that coronary arterial and venous maturation in the initial plexus involve distinct molecular programs. This may be because the coronary endothelium originates from a venous source (the sinus venosus), such that coronary arterial endothelium must first be respecified to an arterial fate. This may necessitate not only VEGF signaling (to initiate arterialization) but also CXCL12 to promote further maturation.

Several features distinguish the role of CXCL12 in coronary vasculogenesis from previously described maturation factors such as Notch, angiopoietin, and ephrin. First, unlike these general factors, CXCL12 is clearly not required in all or even in most vascular compartments. We examined coronary maturation in mutant embryos, and previous studies have noted vascular defects in the gut (Ara et al., 2005), kidney (Takabatake et al., 2009), and skin (Li et al., 2013), but yolk sac and most embryonic vessel beds were normal, and embryo growth, morphology, and viability were normal until late gestation when coronary perfusion becomes required. Second, CXCL12 is not absolutely required for vessel maturation, since coronary artery formation was evident although greatly limited in mutant embryos, and those arteries that did form were able to assemble a smooth muscle layer and become perfused with systemic blood. Importantly, though, coronary vascular defects in *Cxcl12/Cxcr4* mutants were manifest prior to the initiation of perfusion, implying that these defects are not the secondary consequence of impaired flow. CXCL12 therefore appears to facilitate the process of vascular maturation in select organ systems including the heart. This probably occurs in conjunction with more general factors; in this light, Notch signaling has been reported to control *Cxcr4* and *Cxcl12* expression in myeloma and mesenchymal cells (Mirandola et al., 2013; Xie et al., 2013). This role of facilitating vascular maturation may also explain the phenotype observed in the developing gut (Ara et al., 2005) and possibly also in kidney (Takabatake et al., 2009). Finally, unlike Notch, angiopoietin, and ephrin signaling in which both ligand and receptor are expressed by endothelial cells and control vessel maturation largely by autocrine interactions, CXCL12 functions as a paracrine factor that influences adjacent CXCR4-expressing endothelial cells. In coronary development, CXCL12 is expressed by the epicardium and epicardium-derived mesenchymal cells and to a lesser extent by the myocardium (Figure 2), and in the kidney

(J and K) Normal coronary vasculature in E17.5 *Nkx2.5Cre/Cxcr4* mutants and control (J); the asterisk in (K) indicates leaking of excess ink into the ventricular cavity.

(L and M) H&E staining of frontal sections showing normal heart morphology in both control (L) and mutant (M) hearts at E17.5.

Abbreviations: ra, right atria; sv, sinus venosus; rv, right ventricle; endo, endocardium; li, liver; ca, coronary artery; cv, coronary vein; lca, left coronary artery; rca, right coronary artery; sb, septal branch. See also Figure S4.

CXCL12 is expressed by podocytes (Takabatake et al., 2009). The requirement for a nearby source of CXCL12 might explain why only some organ systems utilize it for vascular maturation.

Our prior results demonstrated that the epicardium expresses IGF2, which is required for cardiomyocyte proliferation and expansion of the ventricular wall (Li et al., 2011; Shen et al., 2015). IGF2 has no apparent role in coronary formation or maturation, and in the present study, CXCL12 signaling had no apparent role in the myocardium. These two epicardial factors therefore independently regulate different aspects of heart development. The expansion of the ventricular wall in response to IGF2 initiates from E10 (the time of formation of the epicardium) when growth substrates such as oxygen and glucose can diffuse into the myocardium from the ventricular lumen. As this process progresses, diffusion across the thickening ventricular wall becomes increasingly more limiting. CXCL12 during the E11.5–E14.5 period promotes the assembly of the coronary vasculature, so that the onset of coronary perfusion around E14 provides a new means of distributing materials to the myocardium and thereby supporting heart and embryonic growth to the end of gestation.

EXPERIMENTAL PROCEDURES

Fibrin Bead Assay

Dextran-coated Cytodex 3 microcarriers were coated with HUVECs, resuspended in fibrinogen, and added to wells of a 24-well plate containing thrombin to allow clotting. 1 ml of endothelial basal media containing 2% fetal bovine serum (FBS) with or without VEGF, CXCL12, or AMD3100 was added to each well, and dermal fibroblasts were plated on top of the clot. Beads were photographed at 5× magnification after 3–7 days in culture; sprout number, tube number, branching points, and anastomoses were manually quantified from multiple microscopic fields per well.

Mice

All mice were housed and bred within the animal facility at the University of Southern California in accordance with Institutional Animal Care and Use Committee guidance. All mouse lines used in this study have been described previously, as follows: *Cxcl12* mutant (Ara et al., 2003), conditional *Cxcr4* (Nie et al., 2004), *Tie2Cre* transgenic (Kisanuki et al., 2001), *Nfatc1Cre* (Zhou et al., 2002), *Nkx2.5Cre* knockin (Moses et al., 2001), and conditional *R26lacZ* and *R26YFP* (Soriano, 1999).

India Ink Coronary Artery Perfusion

Hearts were carefully dissected from the thoracic regions of E15.5–E17.5 embryos and transferred to DMEM/10%FBS/heparin on ice. India ink diluted in PSB/heparin was then injected via the ascending aorta by mouth pipetting with a borosilicate glass tube. Hearts were fixed, dehydrated, cleared in benzyl alcohol:benzyl benzoate (1:1), and imaged with a stereomicroscope.

Additional and detailed experimental procedures are described in the Supplemental Information.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures and four figures and can be found with this article online at <http://dx.doi.org/10.1016/j.devcel.2015.03.018>.

ACKNOWLEDGMENTS

This work was supported by NIH grant HL070123 to H.M.S. and grant 14BGIA20500059 to S.R.K. from the American Heart Association. S.C. was supported by a postdoctoral fellowship from the American Heart Association.

H.S. was supported by a postdoctoral fellowship from the California Institute for Regenerative Medicine.

Received: July 24, 2014

Revised: December 5, 2014

Accepted: March 23, 2015

Published: May 26, 2015

REFERENCES

- Ara, T., Nakamura, Y., Egawa, T., Sugiyama, T., Abe, K., Kishimoto, T., Matsui, Y., and Nagasawa, T. (2003). Impaired colonization of the gonads by primordial germ cells in mice lacking a chemokine, stromal cell-derived factor-1 (SDF-1). *Proc. Natl. Acad. Sci. USA* *100*, 5319–5323.
- Ara, T., Tokoyoda, K., Okamoto, R., Koni, P.A., and Nagasawa, T. (2005). The role of CXCL12 in the organ-specific process of artery formation. *Blood* *105*, 3155–3161.
- Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoek, A., Harpal, K., Eberhardt, C., et al. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. *Nature* *380*, 435–439.
- Chen, H.I., Poduri, A., Numi, H., Kivela, R., Saharinen, P., McKay, A.S., Raffrey, B., Churko, J., Tian, X., Zhou, B., et al. (2014). VEGF-C and aortic cardiomyocytes guide coronary artery stem development. *J. Clin. Invest.* *124*, 4899–4914.
- Choudhary, B., Zhou, J., Li, P., Thomas, S., Kaartinen, V., and Sucov, H.M. (2009). Absence of TGFbeta signaling in embryonic vascular smooth muscle leads to reduced lysyl oxidase expression, impaired elastogenesis, and aneurysm. *Genesis* *47*, 115–121.
- Duarte, A., Hirashima, M., Benedito, R., Trindade, A., Diniz, P., Bekman, E., Costa, L., Henrique, D., and Rossant, J. (2004). Dosage-sensitive requirement for mouse *Dll4* in artery development. *Genes Dev.* *18*, 2474–2478.
- Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K.S., Powell-Braxton, L., Hillan, K.J., and Moore, M.W. (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. *Nature* *380*, 439–442.
- Hong, C.C., Peterson, Q.P., Hong, J.Y., and Peterson, R.T. (2006). Artery/vein specification is governed by opposing phosphatidylinositol-3 kinase and MAP kinase/ERK signaling. *Curr. Biol.* *16*, 1366–1372.
- Jain, R.K. (2003). Molecular regulation of vessel maturation. *Nat. Med.* *9*, 685–693.
- Kisanuki, Y.Y., Hammer, R.E., Miyazaki, J., Williams, S.C., Richardson, J.A., and Yanagisawa, M. (2001). Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. *Dev. Biol.* *230*, 230–242.
- Lawson, N.D., Vogel, A.M., and Weinstein, B.M. (2002). sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. *Dev. Cell* *3*, 127–136.
- Li, P., Cavallero, S., Gu, Y., Chen, T.H.P., Hughes, J., Hassan, A.B., Brünig, J.C., Pashmforoush, M., and Sucov, H.M. (2011). IGF signaling directs ventricular cardiomyocyte proliferation during embryonic heart development. *Development* *138*, 1795–1805.
- Li, W., Kohara, H., Uchida, Y., James, J.M., Soneji, K., Cronshaw, D.G., Zou, Y.R., Nagasawa, T., and Mukoyama, Y.S. (2013). Peripheral nerve-derived CXCL12 and VEGF-A regulate the patterning of arterial vessel branching in developing limb skin. *Dev. Cell* *24*, 359–371.
- Ma, Q., Jones, D., Borghesani, P.R., Segal, R.A., Nagasawa, T., Kishimoto, T., Bronson, R.T., and Springer, T.A. (1998). Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. *Proc. Natl. Acad. Sci. USA* *95*, 9448–9453.
- Mirandola, L., Apicella, L., Colombo, M., Yu, Y., Berta, D.G., Platonova, N., Lazzari, E., Lancellotti, M., Bulfamante, G., Cobos, E., et al. (2013). Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1. *Leukemia* *27*, 1558–1566.

- Moses, K.A., DeMayo, F., Braun, R.M., Reecy, J.L., and Schwartz, R.J. (2001). Embryonic expression of an Nkx2-5/Cre gene using ROSA26 reporter mice. *Genesis* 31, 176–180.
- Mukoyama, Y.S., Gerber, H.P., Ferrara, N., Gu, C., and Anderson, D.J. (2005). Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback. *Development* 132, 941–952.
- Nagasawa, T. (2014). CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. *J. Mol. Med.* 92, 433–439.
- Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S., Kitamura, Y., Yoshida, N., Kikutani, H., and Kishimoto, T. (1996). Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. *Nature* 382, 635–638.
- Nakatsu, M.N., Sainson, R.C., Aoto, J.N., Taylor, K.L., Aitkenhead, M., Pérez-del-Pulgar, S., Carpenter, P.M., and Hughes, C.C. (2003). Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. *Microvasc. Res.* 66, 102–112.
- Nie, Y., Waite, J., Brewer, F., Sunshine, M.J., Littman, D.R., and Zou, Y.R. (2004). The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. *J. Exp. Med.* 200, 1145–1156.
- Red-Horse, K., Ueno, H., Weissman, I.L., and Krasnow, M.A. (2010). Coronary arteries form by developmental reprogramming of venous cells. *Nature* 464, 549–553.
- Santiago, B., Calonge, E., Del Rey, M.J., Gutierrez-Cañas, I., Izquierdo, E., Usategui, A., Galindo, M., Alcamí, J., and Pablos, J.L. (2011). CXCL12 gene expression is upregulated by hypoxia and growth arrest but not by inflammatory cytokines in rheumatoid synovial fibroblasts. *Cytokine* 53, 184–190.
- Sengbusch, J.K., He, W., Pinco, K.A., and Yang, J.T. (2002). Dual functions of $\alpha 4 \beta 1$ integrin in epicardial development: initial migration and long-term attachment. *J. Cell Biol.* 157, 873–882.
- Shen, H., Cavallero, S., Estrada, K.D., Sandovici, I., Kumar, S.R., Makita, T., Lien, C.L., Constancia, M., and Sucov, H.M. (2015). Extracardiac control of embryonic cardiomyocyte proliferation and ventricular wall expansion. *Cardiovasc. Res.* 105, 271–278.
- Siekman, A.F., Standley, C., Fogarty, K.E., Wolfe, S.A., and Lawson, N.D. (2009). Chemokine signaling guides regional patterning of the first embryonic artery. *Genes Dev.* 23, 2272–2277.
- Soriano, P. (1999). Generalized lacZ expression with the ROSA26 Cre reporter strain. *Nat. Genet.* 21, 70–71.
- Sun, X., Wei, L., Chen, Q., and Terek, R.M. (2010). CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression. *Mol. Cancer* 9, 17.
- Suri, C., McClain, J., Thurston, G., McDonald, D.M., Zhou, H., Oldmixon, E.H., Sato, T.N., and Yancopoulos, G.D. (1998). Increased vascularization in mice overexpressing angiotensin-1. *Science* 282, 468–471.
- Tachibana, K., Hirota, S., Iizasa, H., Yoshida, H., Kawabata, K., Kataoka, Y., Kitamura, Y., Matsushima, K., Yoshida, N., Nishikawa, S., et al. (1998). The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. *Nature* 393, 591–594.
- Takabatake, Y., Sugiyama, T., Kohara, H., Matsusaka, T., Kurihara, H., Koni, P.A., Nagasawa, Y., Hamano, T., Matsui, I., Kawada, N., et al. (2009). The CXCL12 (SDF-1)/CXCR4 axis is essential for the development of renal vasculature. *J. Am. Soc. Nephrol.* 20, 1714–1723.
- Tian, X., Hu, T., He, L., Zhang, H., Huang, X., Poelmann, R.E., Liu, W., Yang, Z., Yan, Y., Pu, W.T., and Zhou, B. (2013a). Peritruncal coronary endothelial cells contribute to proximal coronary artery stems and their aortic orifices in the mouse heart. *PLoS ONE* 8, e80857.
- Tian, X., Hu, T., Zhang, H., He, L., Huang, X., Liu, Q., Yu, W., He, L., Yang, Z., Zhang, Z., et al. (2013b). Subepicardial endothelial cells invade the embryonic ventricle wall to form coronary arteries. *Cell Res.* 23, 1075–1090.
- Tian, X., Hu, T., Zhang, H., He, L., Huang, X., Liu, Q., Yu, W., He, L., Yang, Z., Yan, Y., et al. (2014). Vessel formation. De novo formation of a distinct coronary vascular population in neonatal heart. *Science* 345, 90–94.
- Wang, H.U., Chen, Z.F., and Anderson, D.J. (1998). Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. *Cell* 93, 741–753.
- Wang, Y., Rattner, A., Zhou, Y., Williams, J., Smallwood, P.M., and Nathans, J. (2012). Norrin/Frizzled4 signaling in retinal vascular development and blood brain barrier plasticity. *Cell* 151, 1332–1344.
- Wu, B., Zhang, Z., Lui, W., Chen, X., Wang, Y., Chamberlain, A.A., Moreno-Rodriguez, R.A., Markwald, R.R., O'Rourke, B.P., Sharp, D.J., et al. (2012). Endocardial cells form the coronary arteries by angiogenesis through myocardial-endocardial VEGF signaling. *Cell* 151, 1083–1096.
- Xie, J., Wang, W., Si, J.W., Miao, X.Y., Li, J.C., Wang, Y.C., Wang, Z.R., Ma, J., Zhao, X.C., Li, Z., et al. (2013). Notch signaling regulates CXCR4 expression and the migration of mesenchymal stem cells. *Cell. Immunol.* 281, 68–75.
- Zhou, B., Cron, R.Q., Wu, B., Genin, A., Wang, Z., Liu, S., Robson, P., and Baldwin, H.S. (2002). Regulation of the murine Nfatc1 gene by NFATc2. *J. Biol. Chem.* 277, 10704–10711.
- Zou, Y.R., Kottmann, A.H., Kuroda, M., Taniuchi, I., and Littman, D.R. (1998). Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. *Nature* 393, 595–599.